Candida is a common intra-oral commensal organism which, in certain circumstances, can become an opportunistic pathogen. Clinical manifestations in the oral cavity can be highly variable and all dental professionals should be familiar with its presentation and management. This paper explores the pathophysiology and presentation of oral candidosis, and examines the dental professionals’ role in management of the condition.
LuSY. Oral Candidosis: Pathophysiology and Best Practice for Diagnosis, Classification, and Successful Management. J Fungi (Basel). 2021;7(7):555.
2.
TalapkoJJuzbašićMMatijevićT, et al. Candida albicans—The Virulence Factors and Clinical Manifestations of Infection. J Fungi (Basel). 2021;7(2):79.
3.
NaglikJRMoyesDLWächtlerB, et al. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect. 2011;13(12-13):963-976.
4.
CiureaCNKosovskiIBMareAD, et al. Candida and Candidiasis—Opportunism Versus Pathogenicity: A Review of the Virulence Traits. Microorganisms. 2020;8(6):857.
5.
WilliamsDWLewisMAO. Oral Microbiology: Isolation and identification of candida from the oral cavity. Oral Dis. 2000;6(1):3-11.
6.
DanilukTTokajukGStokowskaW, et al. Occurrence rate of oral Candida albicans in denture wearer patients. Adv Med Sci. 2006;51(s1):77-80.
7.
MunMYapTAlnuaimiA, et al. Oral candidal carriage in asymptomatic patients. Aust Dent J. 2016;61(2):190-195.
8.
MbaIENwezeEI. Mechanism of Candida pathogenesis: revisiting the vital drivers. Eur J Clin Microbiol Infect Dis. 2020;39(10):1797-1819.
9.
ShareckJBelhumeurP. Modulation of Morphogenesis in Candida albicans by Various Small Molecules. Eukaryot Cell. 2011;10(8):1004-1012.
10.
SudberyPE. Growth of Candida albicans hyphae. Nat Rev Microbiol. 2011;9(10):737-748.
11.
de RepentignyLLewandowskiDJolicoeurP. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev. 2004;17(4):729-759.
GreenfieldRA. Host defense system interactions with Candida. J Med Vet Mycol. 1992;30(2):89-104.
14.
MahajanBBagulNDesaiR, et al. Pseudomembranous Type of Oral Candidiasis is Associated with Decreased Salivary Flow Rate and Secretory Immunoglobulin A Levels. Mycopathologia. 2015;180(1-2):75-80.
15.
FerreiraDTda SilvaPVde Oliveira JuniorHCC, et al. Can There Be a Relationship Between Oral Candidiasis and Candidemia in ICU Patients?Curr Fungal Infect Rep. 2023;17(3):195-201.
16.
EllepolaANBSamaranayakeLP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001;7(4):211-216.
17.
ArendorfTMWalkerDMKingdomRJ, et al. Tobacco smoking and denture wearing in oral candidal leukoplakia. Br Dent J. 1983;155(10):340-343.
18.
DilhariAWeerasekeraMMSiriwardhanaA, et al. Candida infection in oral leukoplakia: an unperceived public health problem. Acta Odontol Scand. 2016;74(7):565-569.
19.
SpeightPMKhurramSAKujanO. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):612-627.
20.
ShuklaKVunILovI, et al. Role of Candida infection in the malignant transformation of oral leukoplakia: A systematic review of observational studies. Transl Res Oral Oncol. 2019;4; 1-10.
21.
SoysaNSSamaranayakeLPEllepolaANB. Antimicrobials as a contributory factor in oral candidosis – a brief overview. Oral Dis. 2008;14(2):138-143.
22.
LewisM. The Role of Antifungal and Antiviral Agents in Primary Dental Care. Prim Dent J. 2014;3(4):59-64.
23.
PuryerJ. Denture stomatitis – a clinical update. Dent Update. 2016;43(6):529-535.
24.
PerićMMiličićBKuzmanović PfićerJ, et al. A Systematic Review of Denture Stomatitis: Predisposing Factors, Clinical Features, Etiology, and Global Candida spp. Distribution. J Fungi (Basel). 2024;10(5):328.
25.
de Sousa PortaSRde Lucena-FerreiraSCda SilvaWJ, et al. Evaluation of sodium hypochlorite as a denture cleanser: a clinical study. Gerodontology. 2015;32(4):260-266.
26.
MylonasPMilwardPMcAndrewR. Denture cleanliness and hygiene: an overview. Br Dent J. 2022;233(1):20-26.
27.
KumarNBrookeABurkeM, et al. The oral management of oncology patients requiring radiotherapy, chemotherapy and/or bone marrow transplantation. Fac Dent J. RCS(Eng). 2013;4(4):200-203.
28.
National Institute for Health and Care Excellence (NICE); British National Formulary (BNF). BNF Treatment summaries: Oropharyngeal fungal infections. [Internet]. London: NICE/BNF; 2025. Available at bnf.nice.org.uk/treatment-summaries/oropharyngeal-fungal-infections [Accessed May 2025].
29.
Scottish Dental Clinical Effectiveness Programme (SDCEP). Drug Prescribing for Dentistry. [Internet]. Dundee: SDCEP; 2025. Available at sdcepdentalprescribing.nhs.scot [Accessed May 2025].
30.
National Institute for Health and Care Excellence (NICE). [Internet]. London: NICE; 2025. Available at nice.org.uk [Accessed May 2025].
31.
KaplanJEMasurHHolmesKK. Guidelines for preventing opportunistic infections among HIV-infected persons – 2002: recommendations of the U.S. Public Health Services and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(RR-8):1-52.
32.
SanglardDCosteAFerrariS. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 2009;9(7):1029-1050.
33.
HofH. A new, broad-spectrum azole antifungal: posaconazole – mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49(s1):2-6.
34.
PiérardGEHermanns-LêTDelvenneP, et al. Miconazole, a pharmacological barrier to skin fungal infections. Expert Opin Pharmacother. 2012;13(8):1187-1194.
